Article (Scientific journals)
Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management.
Boriani, Giuseppe; Lee, Geraldine; Parrini, Iris et al.
2021In European Journal of Preventive Cardiology, 28 (6), p. 611-621
Peer Reviewed verified by ORBi
 

Files


Full Text
zwaa054.pdf
Author postprint (1 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Anticoagulants; Heparin, Low-Molecular-Weight; Administration, Oral; Anticoagulants/adverse effects; Atrial Fibrillation/complications/diagnosis/drug therapy; Heparin, Low-Molecular-Weight/therapeutic use; Humans; Neoplasms/complications/diagnosis/drug therapy; Risk Assessment; Risk Factors; Stroke/diagnosis/epidemiology/etiology; Surveys and Questionnaires; Venous Thromboembolism; Metastasis; Anticoagulation; Atrial fibrillation; Cancer; Direct oral anticoagulants; Low molecular weight heparin; Risk stratification; Stroke; Survey; Survival; Warfarin
Abstract :
[en] BACKGROUND: In patients with active cancer and atrial fibrillation (AF) anticoagulation, thrombotic and bleeding risk still entail uncertainty. AIM: We explored the results of an international survey examining the knowledge and behaviours of a large group of physicians. METHODS AND RESULTS: A web-based survey was completed by 960 physicians (82.4% cardiologists, 75.5% from Europe). Among the currently available anticoagulants for stroke prevention in patients with active cancer, direct oral anticoagulants (DOACs) were preferred by 62.6%, with lower values for low molecular weight heparin (LMWH) (24.1%) and for warfarin (only 7.3%). About 46% of respondents considered that DOACs should be used in all types of cancers except in non-operable gastrointestinal cancers. The lack of controlled studies on bleeding risk (33.5% of respondents) and the risk of drug interactions (31.5%) were perceived as problematic issues associated with use of anticoagulants in cancer. The decision on anticoagulation involved a cardiologist in 27.8% of cases, a cardiologist and an oncologist in 41.1%, and a team approach in 21.6%. The patient also was involved in decision-making, according to ∼60% of the respondents. For risk stratification, use of CHA2DS2-VASc and HAS-BLED scores was considered appropriate, although not specifically validated in cancer patients, by 66.7% and 56.4%, respectively. CONCLUSION: This survey highlights that management of anticoagulation in patients with AF and active cancer is challenging, with substantial heterogeneity in therapeutic choices. Direct oral anticoagulants seems having an emerging role but still the use of LMWH remains substantial, despite the absence of long-term data on thromboprophylaxis in AF.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Boriani, Giuseppe;  Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences,
Lee, Geraldine;  Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's
Parrini, Iris;  Cardiology Division, Mauriziano Hospital, Via Magellano 1, 10128, Turin, Italy.
Lopez-Fernandez, Teresa;  Division of Cardiology, Cardiac Imaging and Cardio-Oncology Unit, La Paz
Lyon, Alexander R ;  Cardio-Oncology Service, Royal Brompton & Harefield NHS Foundation Trust and the
Suter, Thomas;  Cardiology, University Hospital Inselspital, Freiburgstrasse 41G, 3010 Bern,
Van der Meer, Peter;  Department of Cardiology, University of Groningen, University Medical Center
Cardinale, Daniela;  Cardioncology Unit, European Institute of Oncology, I.R.C.C.S., Via Giuseppe
LANCELLOTTI, Patrizio  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie ; Gruppo Villa Maria Care and Research, Maria Cecilia Hospital, Via Corriera
Zamorano, Jose Luis;  University Hospital Ramon y Cajal, CiberCV, Ctra. de Colmenar Viejo km. 9,100
Bax, Jeroen J;  Department of Cardiology, Leiden University Medical Centre (LUMC), Albinusdreef
Asteggiano, Riccardo;  School of Medicine, University of Insubria, Via Ravasi, 2, 21100 Varese, Italy. ; LARC (Laboratorio Analisi e Ricerca Clinica), Corso Venezia, 10, 10155 Turin,
Council of Cardio-Oncology of the European Society of, Cardiology
More authors (3 more) Less
Language :
English
Title :
Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management.
Publication date :
22 May 2021
Journal title :
European Journal of Preventive Cardiology
ISSN :
2047-4873
eISSN :
2047-4881
Publisher :
SAGE Publications Ltd, Gb
Volume :
28
Issue :
6
Pages :
611-621
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
Available on ORBi :
since 18 May 2022

Statistics


Number of views
236 (0 by ULiège)
Number of downloads
353 (0 by ULiège)

Scopus citations®
 
33
Scopus citations®
without self-citations
20
OpenCitations
 
22

Bibliography


Similar publications



Contact ORBi